Comparative Pharmacology
Head-to-head clinical analysis: PONATINIB HYDROCHLORIDE versus SCEMBLIX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PONATINIB HYDROCHLORIDE versus SCEMBLIX.
PONATINIB HYDROCHLORIDE vs SCEMBLIX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ponatinib is a potent oral tyrosine kinase inhibitor that inhibits BCR-ABL, including T315I mutant, as well as VEGFR, PDGFR, FGFR, and SRC kinases.
Selective inhibitor of BCR-ABL1 tyrosine kinase, targeting the myristoyl pocket (STAMP) to induce inactive conformation of BCR-ABL1, including T315I mutant.
45 mg orally once daily with or without food.
200 mg orally once daily with a meal.
None Documented
None Documented
Terminal half-life of approximately 29 hours (range 18–48 h) supporting once-daily dosing; steady-state reached within 7 days.
Terminal elimination half-life approximately 21–23 hours (range 10–35 h). Supports once-daily dosing.
Primarily hepatobiliary excretion; ~87% of dose recovered in feces (mostly as metabolites), <5% in urine as unchanged drug.
Primarily fecal (77%) with minor renal excretion (11%). Biliary excretion contributes to fecal elimination; <1% excreted unchanged in urine.
Category C
Category C
Tyrosine Kinase Inhibitor
Tyrosine Kinase Inhibitor, Antineoplastic